Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease

NCT04652518 is registered in ClinicalTrials.gov with PureTech as lead sponsor.

NCT NCT04652518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04652518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease
Lead sponsor
PureTech
Phase
Phase 2
Overall status
Terminated
Start date
December 11, 2020
Completion date
July 18, 2022
Enrollment
185 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, post-acute covid-19 respiratory disease